Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 2/2011

01.02.2011 | Original Article

Pharmacokinetics in mice and metabolism in murine and human liver fractions of the putative cancer chemopreventive agents 3′,4′,5′,5,7-pentamethoxyflavone and tricin (4′,5,7-trihydroxy-3′,5′-dimethoxyflavone)

verfasst von: Hong Cai, Stewart Sale, Robert G. Britton, Karen Brown, William P. Steward, Andreas J. Gescher

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The flavones tricin (4′,5,7-trihydroxy-3′,5′-dimethoxyflavone) and 3′,4′,5′,5,7-pentamethoxyflavone (PMF) are under development as potential colorectal cancer chemopreventive agents as they reduced adenoma development in the Apc Min mouse model of intestinal carcinogenesis. Here, the pharmacokinetic properties and metabolism of these flavones after oral administration were compared in mice.

Methods

C57BL/6 J mice received an oral bolus of PMF or tricin (807 μmol/kg). Parent flavone and metabolites were analyzed by HPLC/UV in plasma, liver and gastrointestinal tissues. Flavones were incubated with mouse or human hepatic microsomes or 9000xg supernatant (S9), both fortified with a NADPH-generating system and either uridine 5′-diphosphoglucuronic acid (UDPGA, microsomes) or 3′-phosphoadenosine-5′-phosphosulfate (PAPS, S9). Disappearance of substrate was assessed by HPLC/UV, metabolites were characterized by HPLC/MS/MS.

Results

Plasma concentrations and area under the plasma concentration versus time curve for PMF were higher than those for tricin. A mono-O-desmethyl PMF and several isomeric mono-O-desmethyl PMF glucuronides and sulfonates were major PMF metabolites in murine plasma, liver and intestinal tissue. In murine and human liver fractions, in vitro metabolic removal of tricin was faster than that of PMF. On kinetic analysis of metabolite generation in these incubations, apparent maximal velocity (V max) values for the generation of tricin O-glucuronide or O-sulfonate were consistently several fold higher than those characterizing the production of mono-O-desmethyl PMF glucuronides or sulfonates via the intermediacy of O-desmethyl PMF.

Conclusions

The results suggest that inclusion of methoxy moieties confers metabolic stability onto the flavone scaffold.
Literatur
1.
Zurück zum Zitat Rice Evans CA, Packer L (2003) Flavonoids in health and disease, 2nd edn. Marcel Dekker Inc, New York Rice Evans CA, Packer L (2003) Flavonoids in health and disease, 2nd edn. Marcel Dekker Inc, New York
2.
Zurück zum Zitat Manach C, Donovan JL (2004) Pharmacokinetics and metabolism of dietary flavonoids in humans. Free Rad Res 38:771–785CrossRef Manach C, Donovan JL (2004) Pharmacokinetics and metabolism of dietary flavonoids in humans. Free Rad Res 38:771–785CrossRef
3.
Zurück zum Zitat Cai H, Tunstall RG, Al-Fayez M, Platton S, Steward WP, Gescher AJ (2005) The rice bran constituent tricin potently inhibits cyclooxygenase enzymes and interferes with intestinal carcinogenesis in Apc Min mice. Mol Cancer Ther 4:1288–1292CrossRef Cai H, Tunstall RG, Al-Fayez M, Platton S, Steward WP, Gescher AJ (2005) The rice bran constituent tricin potently inhibits cyclooxygenase enzymes and interferes with intestinal carcinogenesis in Apc Min mice. Mol Cancer Ther 4:1288–1292CrossRef
4.
Zurück zum Zitat Cai H, Sale S, Schmid R, Britton RG, Brown K, Steward WP, Gescher AJ (2009) Flavones as colorectal cancer chemopreventive agents—phenol-O-methylation enhances efficacy. Cancer Prev Res 2:743–750CrossRef Cai H, Sale S, Schmid R, Britton RG, Brown K, Steward WP, Gescher AJ (2009) Flavones as colorectal cancer chemopreventive agents—phenol-O-methylation enhances efficacy. Cancer Prev Res 2:743–750CrossRef
5.
Zurück zum Zitat Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, Dove WF (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256:668–670CrossRefPubMed Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, Dove WF (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256:668–670CrossRefPubMed
6.
Zurück zum Zitat Kinoshita T, Firman K (1997) Myrecetin, 5, 7, 3′, 4′, 5′-pentamethyl ether and other methylated flavonoids from Murraya paniculata. Phytochem 45:179–181CrossRef Kinoshita T, Firman K (1997) Myrecetin, 5, 7, 3′, 4′, 5′-pentamethyl ether and other methylated flavonoids from Murraya paniculata. Phytochem 45:179–181CrossRef
7.
Zurück zum Zitat Tomazela DM, Pupo MT, Passador AP, da Silva MFDF, Vieira PC, Fernandes JB, Fo ER, Oliva G, Pirani JR (2000) Pyrano chalcones and a flavone from Neuraputia magnifica and their Trypanosoma cruzi glycosomal glyceraldehydes-3-phosphate dehydrogenase-inhibitory activities. Phytochem 55:643–651CrossRef Tomazela DM, Pupo MT, Passador AP, da Silva MFDF, Vieira PC, Fernandes JB, Fo ER, Oliva G, Pirani JR (2000) Pyrano chalcones and a flavone from Neuraputia magnifica and their Trypanosoma cruzi glycosomal glyceraldehydes-3-phosphate dehydrogenase-inhibitory activities. Phytochem 55:643–651CrossRef
8.
Zurück zum Zitat Walle T, Ta N, Kawamori T, Wen X, Tsuji PA, Walle UK (2007) Cancer chemopreventive properties of orally bioavailable flavonoids—methylated versus unmethylated flavones. Biochem Pharmacol 73:1288–1296CrossRefPubMed Walle T, Ta N, Kawamori T, Wen X, Tsuji PA, Walle UK (2007) Cancer chemopreventive properties of orally bioavailable flavonoids—methylated versus unmethylated flavones. Biochem Pharmacol 73:1288–1296CrossRefPubMed
9.
Zurück zum Zitat Wen X, Walle T (2006) Methylated flavonoids have greatly improved intestinal absorption and metabolic stability. Drug Metab Dispos 34:1786–1792CrossRefPubMed Wen X, Walle T (2006) Methylated flavonoids have greatly improved intestinal absorption and metabolic stability. Drug Metab Dispos 34:1786–1792CrossRefPubMed
10.
Zurück zum Zitat Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Brit J Cancer 77:1–10 Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Brit J Cancer 77:1–10
11.
Zurück zum Zitat Cai H, Brown K, Steward WP, Gescher AJ (2009) Determination of 3′, 4′, 5′, 5, 7-pentamethoxyflavone in the plasma and intestinal mucosa of mice by HPLC with UV detection. Biomed Chromatog 23:335–339CrossRef Cai H, Brown K, Steward WP, Gescher AJ (2009) Determination of 3′, 4′, 5′, 5, 7-pentamethoxyflavone in the plasma and intestinal mucosa of mice by HPLC with UV detection. Biomed Chromatog 23:335–339CrossRef
12.
Zurück zum Zitat Cai H, Steward WP, Gescher AJ (2005) Determination of the putative cancer chemopreventive flavone tricin in plasma and tissue of mice by HPLC with UV-visible detection. Biomed Chromatogr 19:518–522CrossRefPubMed Cai H, Steward WP, Gescher AJ (2005) Determination of the putative cancer chemopreventive flavone tricin in plasma and tissue of mice by HPLC with UV-visible detection. Biomed Chromatogr 19:518–522CrossRefPubMed
13.
Zurück zum Zitat Bradford MM (1976) A rapid and sensitive for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt Biochem 72:248–254CrossRefPubMed Bradford MM (1976) A rapid and sensitive for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt Biochem 72:248–254CrossRefPubMed
14.
Zurück zum Zitat Cai H, Boocock DJ, Steward WP, Gescher AJ (2007) Tissue distribution in mice and metabolism in murine and human liver of apigenin and tricin, flavones with putative cancer chemopreventive properties. Cancer Chemother Pharmacol 60:257–266CrossRefPubMed Cai H, Boocock DJ, Steward WP, Gescher AJ (2007) Tissue distribution in mice and metabolism in murine and human liver of apigenin and tricin, flavones with putative cancer chemopreventive properties. Cancer Chemother Pharmacol 60:257–266CrossRefPubMed
15.
Zurück zum Zitat Mabry TJ, Markham KR, Thomas MB (1970) The systematic identification of flavonoids. Springer, Heidelberg Mabry TJ, Markham KR, Thomas MB (1970) The systematic identification of flavonoids. Springer, Heidelberg
16.
Zurück zum Zitat Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60:5040–5044PubMed Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60:5040–5044PubMed
17.
Zurück zum Zitat Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJA (1993) Treatment of colonic and rectal adenoma s with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316CrossRefPubMed Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJA (1993) Treatment of colonic and rectal adenoma s with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316CrossRefPubMed
18.
Zurück zum Zitat Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu Goris M, Newmark HL, Lipkin ML, De Cosse JJ, Bertagnolli MM (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56:2556–2560PubMed Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Abreu Goris M, Newmark HL, Lipkin ML, De Cosse JJ, Bertagnolli MM (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56:2556–2560PubMed
19.
Zurück zum Zitat Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B, Godio L, Patterson S, Rodriguez-Bigas MA, Jester SL, King KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmerman S, Sherman JW, Kelloff G (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952CrossRefPubMed Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B, Godio L, Patterson S, Rodriguez-Bigas MA, Jester SL, King KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmerman S, Sherman JW, Kelloff G (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952CrossRefPubMed
20.
Zurück zum Zitat Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D (2007) The use of aspirin for primary prevention of colorectal cancer: A systematic review prepared for the US Preventive Services Task Force. Ann Intern Med 146:365–375PubMed Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D (2007) The use of aspirin for primary prevention of colorectal cancer: A systematic review prepared for the US Preventive Services Task Force. Ann Intern Med 146:365–375PubMed
21.
Zurück zum Zitat Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli MM (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080CrossRefPubMed Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli MM (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080CrossRefPubMed
Metadaten
Titel
Pharmacokinetics in mice and metabolism in murine and human liver fractions of the putative cancer chemopreventive agents 3′,4′,5′,5,7-pentamethoxyflavone and tricin (4′,5,7-trihydroxy-3′,5′-dimethoxyflavone)
verfasst von
Hong Cai
Stewart Sale
Robert G. Britton
Karen Brown
William P. Steward
Andreas J. Gescher
Publikationsdatum
01.02.2011
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 2/2011
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-010-1313-1

Weitere Artikel der Ausgabe 2/2011

Cancer Chemotherapy and Pharmacology 2/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.